Repron Therapeutics
Epigenetic silencing platform for tumor recurrence repression.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
* | €2.0m | Seed | |
| Total Funding | 000k | ||
| EUR | 2023 | 2024 |
|---|---|---|
| Revenues | 0000 | 0000 |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| % profit margin | - | (18640300 %) |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Company filings or news article
Related Content
Repron Therapeutics is a biotechnology company specializing in the development of innovative therapies for reproductive health and associated disorders. The company focuses on pioneering treatments that address unmet needs in the field of reproductive medicine, aiming to improve patient outcomes and quality of life.
Repron Therapeutics leverages advanced scientific research and cutting-edge technology to create solutions for complex reproductive issues. Their approach involves a deep understanding of the underlying biological mechanisms and the application of novel therapeutic strategies to target these mechanisms effectively.
The company's research pipeline includes potential treatments for various conditions, including infertility, hormone imbalances, and other reproductive health challenges. Repron Therapeutics is dedicated to advancing its therapeutic offerings through rigorous clinical development and collaboration with leading research institutions and healthcare providers.
By driving innovation in reproductive medicine, Repron Therapeutics aims to make a significant impact on patient care and contribute to the broader field of biomedicine. The company's commitment to scientific excellence and patient-centered solutions underscores its mission to address critical gaps in reproductive health.